Simply Wall St.
Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans
📉
AI Sentiment
Negative
2/10
- Home
- BSX
as of 03-06-2026 3:38pm EST
$71.67
$1.32
-1.82%
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 137.8B | IPO Year: | 2010 |
| Target Price: | $109.15 | AVG Volume (30 days): | 14.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.94 | EPS Growth: | 55.20 |
| 52 Week Low/High: | $70.75 - $109.50 | Next Earning Date: | 05-06-2026 |
| Revenue: | $9,076,000,000 | Revenue Growth: | 12.49% |
| Revenue Growth (this year): | 12.04% | Revenue Growth (next year): | 10.48% |
| P/E Ratio: | 37.64 | Index: | |
| Free Cash Flow: | 3.7B | FCF Growth: | +38.30% |
AI-Powered BSX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 77.30%
77.30%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
Mahoney Michael F
Sell
Chairman, President & CEO
BSX Feb 2, 2026
Avg Cost/Share
$93.77
Shares
160,901
Total Value
$15,043,394.38
Owned After
1,571,436
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mahoney Michael F | BSX | Chairman, President & CEO | Feb 2, 2026 | Sell | $93.77 | 160,901 | $15,043,394.38 | 1,571,436 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 4, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 4, 2026 · 100% conf.
AI Prediction SELL
1D
-1.58%
$74.21
5D
-2.59%
$73.45
20D
-0.04%
$75.37
Price: $75.40 Prob +5D: 0% AUC: 1.000
0000885725-26-000006
bsx-202602040000885725false00008857252026-02-042026-02-040000885725us-gaap:CommonStockMember2026-02-042026-02-040000885725bsx:SeniorNotedue2027Member2026-02-042026-02-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 4, 2026
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234 (Address of Principal Executive Offices) (Zip Code)
508 683-4000 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value per shareBSXNew York Stock Exchange 0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On February 4, 2026, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. A copy of the release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Boston Scientific Corporation dated February 4, 2026
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:February 4, 2026BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary
2025 Q3 Q3 2025 Earnings
8-K Oct 22, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 22, 2025
0000885725-25-000046
bsx-202510220000885725false00008857252025-10-222025-10-220000885725us-gaap:CommonStockMember2025-10-222025-10-220000885725bsx:SeniorNotedue2027Member2025-10-222025-10-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 22, 2025
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234 (Address of Principal Executive Offices) (Zip Code)
508 683-4000 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value per shareBSXNew York Stock Exchange 0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On October 22, 2025, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of the release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Boston Scientific Corporation dated October 22, 2025
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:October 22, 2025BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary
2025 Q2 Q2 2025 Earnings
8-K Jul 23, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 23, 2025
0000885725-25-000039
bsx-202507230000885725false00008857252025-07-232025-07-230000885725us-gaap:CommonStockMember2025-07-232025-07-230000885725bsx:SeniorNotedue2027Member2025-07-232025-07-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 23, 2025
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234 (Address of Principal Executive Offices) (Zip Code)
508 683-4000 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value per shareBSXNew York Stock Exchange 0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On July 23, 2025, Boston Scientific Corporation issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of the release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Boston Scientific Corporation dated July 23, 2025
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:July 23, 2025BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Simply Wall St.
Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
📊
AI Sentiment
Positive
6/10
Zacks
Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
📊
AI Sentiment
Positive
6/10
PR Newswire
Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
➖
AI Sentiment
Neutral
5/10
Zacks
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
📊
AI Sentiment
Positive
7/10
StockStory
1 Healthcare Stock to Target This Week and 2 Facing Challenges
📊
AI Sentiment
Positive
6/10
Motley Fool
3 Reasons Boston Scientific Stock Could Quietly 5X as the World Ages
📈
AI Sentiment
Highly Positive
9/10
Compare BSX vs Leading Stocks
See how BSX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.